Value
3.3/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Fwd P/E | 1.9 |
| PEG | 9.7 |
| Analyst target | 5.0 |
- ▸Forward P/E: 60.3x
- ▸PEG: 0.56
AXON · Why this verdict
Why Axon Enterprise (AXON) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
A 34% year-over-year revenue growth rate, three of four recent earnings beats, and analyst consensus implying 34% upside at a roughly 4.9-to-1 reward-to-risk ratio make the fundamental and valuation cases compelling — yet a death cross and confirmed price downtrend with a 200-day moving average declining at -8.6% per month create a near-term technical headwind that argues for patience rather than adding at current levels.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analyst consensus sets a price target 34% above the current level, and the reward-to-risk ratio is roughly 4.9-to-1 in the investor's favor — a wide margin that can absorb considerable near-term volatility and still produce a favorable outcome if the growth trajectory is maintained. Price targets | The share price moves more than 20% toward the analyst price target over the next 12 months as quarterly growth data validates the consensus view. | ↑Improving |
| CounterAnalyst targets on high-growth names can lag or be cut; the 34% gap to target may narrow not through price appreciation but through target reductions if the confirmed technical downtrend persists and institutional selling continues. | ||
Despite 34% revenue growth, only 30% of net income converts to free cash flow, indicating the business is consuming substantial capital to sustain its growth rate. Business quality overall is below average, limiting the safety margin if growth momentum decelerates. Quality breakdown | Free cash flow as a percentage of net income improves to at least 60% over the next four quarters as the growth investment cycle begins to mature. | ↑Improving |
| CounterA Piotroski financial health score of 8 out of 9 and a healthy current ratio suggest the balance sheet is sound; the low near-term FCF conversion may be a deliberate and time-limited investment choice rather than a structural earnings quality problem. | ||
Revenue expanded 34% year-over-year, placing the company at the top of its peer set on growth, and three of the four most recent earnings quarters were beats — including surpluses of +34.5% and +45% above consensus in successive quarters. The two most recent prints were both beats, sustaining the delivery track record. Growth breakdown | Revenue growth sustains above 25% year-over-year for the next four quarters, and earnings beats continue in at least 2 of the next 3 quarters. | ↓Deteriorating |
| CounterA forward P/E near 42x prices in an extended growth runway without a stumble; the single quarterly miss of -24% below consensus demonstrates that execution can slip, and at this multiple any miss would likely trigger an outsized price reaction. | ||
The price is trading below the 200-day moving average on a slope declining at -8.6% over the past 30 days, and a death cross pattern is in place — conditions indicating sellers have the near-term advantage. Falling on-balance volume confirms distribution rather than accumulation at current levels. Momentum breakdown | Price recovers above the 200-day moving average and on-balance volume reverses to an uptrend, both sustained for more than 10 consecutive trading days, confirming the downtrend has ended. | ↓Deteriorating |
| CounterThe 34% upside to analyst consensus and a 4.9-to-1 reward-to-risk ratio suggest the market may be creating an attractively priced entry point; severe technical dislocations in high-growth names often overshoot to the downside before fundamentals reassert themselves. | ||
Analyst consensus sets a price target 34% above the current level, and the reward-to-risk ratio is roughly 4.9-to-1 in the investor's favor — a wide margin that can absorb considerable near-term volatility and still produce a favorable outcome if the growth trajectory is maintained.
↑ImprovingPrice targets
- Expectation
- The share price moves more than 20% toward the analyst price target over the next 12 months as quarterly growth data validates the consensus view.
CounterAnalyst targets on high-growth names can lag or be cut; the 34% gap to target may narrow not through price appreciation but through target reductions if the confirmed technical downtrend persists and institutional selling continues.
Despite 34% revenue growth, only 30% of net income converts to free cash flow, indicating the business is consuming substantial capital to sustain its growth rate. Business quality overall is below average, limiting the safety margin if growth momentum decelerates.
↑ImprovingQuality breakdown
- Expectation
- Free cash flow as a percentage of net income improves to at least 60% over the next four quarters as the growth investment cycle begins to mature.
CounterA Piotroski financial health score of 8 out of 9 and a healthy current ratio suggest the balance sheet is sound; the low near-term FCF conversion may be a deliberate and time-limited investment choice rather than a structural earnings quality problem.
Revenue expanded 34% year-over-year, placing the company at the top of its peer set on growth, and three of the four most recent earnings quarters were beats — including surpluses of +34.5% and +45% above consensus in successive quarters. The two most recent prints were both beats, sustaining the delivery track record.
↓DeterioratingGrowth breakdown
- Expectation
- Revenue growth sustains above 25% year-over-year for the next four quarters, and earnings beats continue in at least 2 of the next 3 quarters.
CounterA forward P/E near 42x prices in an extended growth runway without a stumble; the single quarterly miss of -24% below consensus demonstrates that execution can slip, and at this multiple any miss would likely trigger an outsized price reaction.
The price is trading below the 200-day moving average on a slope declining at -8.6% over the past 30 days, and a death cross pattern is in place — conditions indicating sellers have the near-term advantage. Falling on-balance volume confirms distribution rather than accumulation at current levels.
↓DeterioratingMomentum breakdown
- Expectation
- Price recovers above the 200-day moving average and on-balance volume reverses to an uptrend, both sustained for more than 10 consecutive trading days, confirming the downtrend has ended.
CounterThe 34% upside to analyst consensus and a 4.9-to-1 reward-to-risk ratio suggest the market may be creating an attractively priced entry point; severe technical dislocations in high-growth names often overshoot to the downside before fundamentals reassert themselves.
Per-dimension breakdown
Quality
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 2.1 |
| ROA | 0.3 |
| Gross margin | 7.9 |
| Op margin | 2.1 |
| Net margin | 3.1 |
| Current ratio | 7.4 |
| FCF quality | 7.6 |
| Moat | 7.1 |
| Piotroski F | 8.9 |
- ▸Strong Piotroski F-Score: 8/9
Growth
5.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 0.0 |
- ▸Strong growth: 35% YoY
Momentum
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 4.1 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.1 |
| Analyst rating | 7.5 |
| Price target | 7.2 |
Insider
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Modest insider selling — $28,422,981 (0.055% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.7 |
| quality rank | 4.2 |
| growth rank | 7.3 |
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.0 |
| support resistance | 2.7 |
| 52w position | 3.5 |
| gap | 6.0 |
Risk (lower is worse)
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.4 |
| days to cover | 6.7 |
| volatility | 0.0 |
| put call | 5.6 |
| implied vol | 2.8 |
| beta | 5.4 |
| debt equity | 8.0 |
- ▸High IV: 63%
- ▸Concentration risks: 2 MED (10-K Item 1A)
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 4.1 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:7.4>=5.5
- INSIDER:OK
- NEWS_BOOST:ANALYST:0.40
- EARNINGS_PROXIMITY:83d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.3<1.5@spot
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.27
Upside
+4.0%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 63, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — Beta 1.40>1.3
Investment implication
The F-path SELL output reflects an overall score of 5.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Momentum at 7.4) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:0.3<1.5@spot) reinforce the read. Current asymmetry R:R is 0.27 — supplementary context, not the trigger for this path.
The strongest dimensions are Momentum at 7.4, Sentiment at 6.6, and Insider at 5.9; the weakest are Value at 3.3, Technical at 3.5, and Peer rank at 4.3. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.27 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Exceptional Revenue Growth Beat Streak
Trip ifRevenue growth falls below 20% year-over-year for 2 consecutive quarters.
- P2Material Analyst Upside Favorable Risk Reward
Trip ifAnalyst consensus price target falls below $500, reducing implied upside to less than 15% from current levels.
- P3Confirmed Downtrend Death Cross
Trip ifPrice rallies above the 200-day moving average and sustains above it for more than 10 consecutive trading days.
- P4Below Average Quality Fcf Conversion
Trip ifFree cash flow as a percentage of net income rises above 60% for 2 consecutive quarters.